Arjun Pennathur
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Arjun Pennathur has a total of 470 co-authors. Here are the top co-authors by number of shared publications:
- James D. Luketich
Department of Cardiothoracic Surgery, University of Pittsburgh School of Medicine, Pittsburgh, PA 15213, USA
18 shared publications James D. Luketich
Department of Cardiothoracic Surgery, University of Pittsburgh School of Medicine, University of Pittsburgh Medical Center, and UPMC Hillman Cancer Center Pittsburgh, Pa
11 shared publicationsMatthew J. Schuchert
Department of Cardiothoracic Surgery, University of Pittsburgh School of Medicine, University of Pittsburgh Medical Center, and UPMC Hillman Cancer Center Pittsburgh, Pa
9 shared publicationsOmar Awais
Department of Cardiothoracic Surgery, University of Pittsburgh School of Medicine, University of Pittsburgh Medical Center, and UPMC Hillman Cancer Center Pittsburgh, Pa
9 shared publicationsWilliam E. Gooding
Department of Cardiothoracic Surgery, UPMC Hillman Cancer Center Biostatistics Facility, Pittsburgh, Pa
9 shared publicationsNeil A. Christie
Department of Cardiothoracic Surgery, University of Pittsburgh School of Medicine, University of Pittsburgh Medical Center, and UPMC Hillman Cancer Center Pittsburgh, Pa
5 shared publications
Latest Publications
- Open Access
- 18 December 2025
- Published by American Society for Clinical Investigation in Journal of Clinical Investigation
- Vol. 136 (4)
MET alterations are enriched in lung adenocarcinoma brain metastases, defining a distinct biologic subtype
Non–small cell lung cancer exhibits the highest rates of brain metastases (BMs) among all solid tumors, presenting a major clinical challenge. The development of novel therapeutic strategies targeting BMs is clearly needed. We identified a significant enrichment of MET amplification in lung adenocarcinoma (LUAD) BMs compared with primary LUAD and extracranial metastases in oncogene driver–negative patients. Of note, MET -amplified BMs were responsive to MET inhibitors in vivo, including models with acquired MET amplification at the time of metastasis. MET alterations (amplifications and/or mutations) were also more frequently detected in circulating tumor DNA from patients with LUAD BMs than in those without BMs. MET- altered BMs also demonstrated unique genomic features compared with non– MET- altered BMs. Transcriptomic analyses revealed that in contrast to MET WT BMs, MET -amplified BMs exhibited a more inflamed tumor microenvironment and displayed evidence of metabolic adaptation, particularly a reliance on glycolysis in contrast to OXPHOS in MET WT BMs. Furthermore, MET -amplified BMs demonstrated evidence of epithelial-mesenchymal transition signaling, including increased expression of TWIST1. Patients with MET -amplified BMs had significantly shorter overall survival. These findings highlight MET amplification as a critical driver of LUAD BMs, emphasizing its potential as a therapeutic target.
- 18 December 2025
- Published by American Society for Clinical Investigation in Journal of Clinical Investigation
- Vol. 136 (4)
Open AccessMET alterations are enriched in lung adenocarcinoma brain metastases, defining a distinct biologic subtype
Non–small cell lung cancer exhibits the highest rates of brain metastases (BMs) among all solid tumors, presenting a major clinical challenge. The development of novel therapeutic strategies targeting BMs is clearly needed. We identified a significant enrichment of MET amplification in lung adenocarcinoma (LUAD) BMs compared with primary LUAD and extracranial metastases in oncogene driver–negative patients. Of note, MET -amplified BMs were responsive to MET inhibitors in vivo, including models with acquired MET amplification at the time of metastasis. MET alterations (amplifications and/or mutations) were also more frequently detected in circulating tumor DNA from patients with LUAD BMs than in those without BMs. MET- altered BMs also demonstrated unique genomic features compared with non– MET- altered BMs. Transcriptomic analyses revealed that in contrast to MET WT BMs, MET -amplified BMs exhibited a more inflamed tumor microenvironment and displayed evidence of metabolic adaptation, particularly a reliance on glycolysis in contrast to OXPHOS in MET WT BMs. Furthermore, MET -amplified BMs demonstrated evidence of epithelial-mesenchymal transition signaling, including increased expression of TWIST1. Patients with MET -amplified BMs had significantly shorter overall survival. These findings highlight MET amplification as a critical driver of LUAD BMs, emphasizing its potential as a therapeutic target.
- Open Access
- 21 August 2025
- Published by Elsevier in The Journal of Thoracic and Cardiovascular Surgery
- Vol. 171 (2) , 500-509.e1
Image-guided radiofrequency ablation for treatment of stage I non–small cell lung cancer in 111 high-risk patients: Analysis of prognostic variables
- 21 August 2025
- Published by Elsevier in The Journal of Thoracic and Cardiovascular Surgery
- Vol. 171 (2) , 500-509.e1
Open AccessImage-guided radiofrequency ablation for treatment of stage I non–small cell lung cancer in 111 high-risk patients: Analysis of prognostic variables
- Open Access
- 2 July 2025
- Published by Elsevier in The Journal of Thoracic and Cardiovascular Surgery
- Vol. 170 (5) , 1295-1303.e1
Analysis of outcomes of reoperative fundoplication in more than 500 patients after failed primary antireflux surgery: Experience over two decades
- 2 July 2025
- Published by Elsevier in The Journal of Thoracic and Cardiovascular Surgery
- Vol. 170 (5) , 1295-1303.e1
Open AccessAnalysis of outcomes of reoperative fundoplication in more than 500 patients after failed primary antireflux surgery: Experience over two decades
- Open Access
A Multicenter Pilot Study of MUC1 Vaccine in Current and Former Smokers at High Risk for Lung Cancer
Background Smoking is the most common etiology for lung cancer and smoking cessation does not eliminate the risk. Mucin (MUC)1 glycoprotein is aberrantly expressed in lung carcinomas and premalignant lung lesions. We explored whether a MUC1 vaccine might be effective in halting neoplastic development and progression in individuals at high risk for lung cancer. Methods We conducted a multicenter trial of a MUC1 vaccine in current and former heavy smokers to evaluate immunogenicity and safety. Smoking history of ≥30 pack-years and CT chest showing either no nodules or nodules < 6 mm were inclusion criteria. A vaccine containing MUC1 peptide was administered at weeks 0, 2 and 10. Blood was collected pre-vaccine administration, 2 weeks after each vaccine, and at week 24. Immunogenicity (primary endpoint) and the presence of myeloid-derived suppressor cells (MDSC) and regulatory T cells (secondary endpoints) were assessed. Adverse events and toxicities were monitored. Results Of 77 individuals screened, 50 were registered and 45 completed the study (27 current and 18 former smokers). The vaccine was well-tolerated. Four current (14.8%) and 2 former smokers (11.1%) developed anti-MUC1 IgG titers ≥2 fold higher at week 12 as compared with baseline, with an overall immune response rate of 13.3% (95% CI 5.1–26.8%). We found high circulating levels of immunosuppressive MDSCs in both current and former smokers. Conclusions Administering a potentially preventive vaccine is feasible and safe in individuals at high risk for lung cancer. However, this cohort exhibited a high level of immune suppression, previously documented only in patients with advanced lung cancer. Nonetheless, a vaccine-induced immune response was noted in 13% of participants. Further work is required to refine participant selection, understand the factors driving immunosuppression, and counteract these factors to apply immunoprevention strategies in this high-risk population. Translational Relevance Vaccines targeting antigens aberrantly expressed on lung cancers and their precursors offer the potential for a relatively non-invasive prevention strategy. Worldwide, lung cancer remains the most important cause of cancer-related mortality, and an immunoprevention approach, if successful, has the potential to save many lives by prevention of lung cancer. All epithelial tumors, including lung cancer, express high levels of abnormal mucin (MUC)1 and MUC1-based therapeutic vaccines can increase this immune response to aberrant expressed MUC1 to therapeutic levels. We conducted a multicenter trial to evaluate the immunogenicity and safety of a MUC1 preventive vaccine in individuals with a significant smoking history and at high risk of developing lung cancer. The MUC1 vaccine was safe and elicited an immune response in 13%, which was lower than anticipated. Unexpectedly, we observed a high level of immune suppression in this cohort of heavy smokers, which has been previously documented in individuals who already have lung cancer. Although immunoprevention strategies are promising for reducing the risk of lung cancer in current and former heavy smokers, the immune environment induced by smoking, and the factors that drive immunosuppression are crucial barriers that must be overcome by well-designed immunoprevention strategies for lung cancer.
Open AccessA Multicenter Pilot Study of MUC1 Vaccine in Current and Former Smokers at High Risk for Lung Cancer
Background Smoking is the most common etiology for lung cancer and smoking cessation does not eliminate the risk. Mucin (MUC)1 glycoprotein is aberrantly expressed in lung carcinomas and premalignant lung lesions. We explored whether a MUC1 vaccine might be effective in halting neoplastic development and progression in individuals at high risk for lung cancer. Methods We conducted a multicenter trial of a MUC1 vaccine in current and former heavy smokers to evaluate immunogenicity and safety. Smoking history of ≥30 pack-years and CT chest showing either no nodules or nodules < 6 mm were inclusion criteria. A vaccine containing MUC1 peptide was administered at weeks 0, 2 and 10. Blood was collected pre-vaccine administration, 2 weeks after each vaccine, and at week 24. Immunogenicity (primary endpoint) and the presence of myeloid-derived suppressor cells (MDSC) and regulatory T cells (secondary endpoints) were assessed. Adverse events and toxicities were monitored. Results Of 77 individuals screened, 50 were registered and 45 completed the study (27 current and 18 former smokers). The vaccine was well-tolerated. Four current (14.8%) and 2 former smokers (11.1%) developed anti-MUC1 IgG titers ≥2 fold higher at week 12 as compared with baseline, with an overall immune response rate of 13.3% (95% CI 5.1–26.8%). We found high circulating levels of immunosuppressive MDSCs in both current and former smokers. Conclusions Administering a potentially preventive vaccine is feasible and safe in individuals at high risk for lung cancer. However, this cohort exhibited a high level of immune suppression, previously documented only in patients with advanced lung cancer. Nonetheless, a vaccine-induced immune response was noted in 13% of participants. Further work is required to refine participant selection, understand the factors driving immunosuppression, and counteract these factors to apply immunoprevention strategies in this high-risk population. Translational Relevance Vaccines targeting antigens aberrantly expressed on lung cancers and their precursors offer the potential for a relatively non-invasive prevention strategy. Worldwide, lung cancer remains the most important cause of cancer-related mortality, and an immunoprevention approach, if successful, has the potential to save many lives by prevention of lung cancer. All epithelial tumors, including lung cancer, express high levels of abnormal mucin (MUC)1 and MUC1-based therapeutic vaccines can increase this immune response to aberrant expressed MUC1 to therapeutic levels. We conducted a multicenter trial to evaluate the immunogenicity and safety of a MUC1 preventive vaccine in individuals with a significant smoking history and at high risk of developing lung cancer. The MUC1 vaccine was safe and elicited an immune response in 13%, which was lower than anticipated. Unexpectedly, we observed a high level of immune suppression in this cohort of heavy smokers, which has been previously documented in individuals who already have lung cancer. Although immunoprevention strategies are promising for reducing the risk of lung cancer in current and former heavy smokers, the immune environment induced by smoking, and the factors that drive immunosuppression are crucial barriers that must be overcome by well-designed immunoprevention strategies for lung cancer.
- Open Access
- 7 May 2025
- Published by MDPI AG in Biomolecules
- Vol. 15 (5) , 678
Hyperthermic Intrathoracic Chemoperfusion and the Role of Adjunct Immunotherapy for the Treatment of Pleural Mesothelioma
Pleural mesothelioma (PM) is an aggressive cancer originating from the mesothelial lining of the pleura, with a rising global incidence since the mid-20th century due to asbestos and erionite exposure. PM accounts for 80–90% of all mesothelioma cases and is histologically classified into three subtypes—epithelioid, sarcomatoid, and biphasic— with epithelioid carrying the most favorable prognosis. Despite advances in surgery, chemotherapy, radiotherapy, and immunotherapy, PM prognosis remains poor, necessitating more effective, multimodal strategies. Hyperthermic intrathoracic chemoperfusion (HITHOC) has emerged as a promising adjunct to cytoreductive surgery by delivering heated chemotherapy directly to the pleural cavity, potentially improving survival—especially in patients with epithelioid PM. Combining HITHOC with post-surgical immunotherapy represents a novel approach to enhancing both local and systemic anti-tumor responses and targeting microscopic disease and distant metastases. This review explores surgical outcomes after surgery for PM, the therapeutic synergy of HITHOC and immunotherapy, ongoing clinical trials evaluating this multimodal strategy, and its implications for future patient care.
- 7 May 2025
- Published by MDPI AG in Biomolecules
- Vol. 15 (5) , 678
Open AccessHyperthermic Intrathoracic Chemoperfusion and the Role of Adjunct Immunotherapy for the Treatment of Pleural Mesothelioma
Pleural mesothelioma (PM) is an aggressive cancer originating from the mesothelial lining of the pleura, with a rising global incidence since the mid-20th century due to asbestos and erionite exposure. PM accounts for 80–90% of all mesothelioma cases and is histologically classified into three subtypes—epithelioid, sarcomatoid, and biphasic— with epithelioid carrying the most favorable prognosis. Despite advances in surgery, chemotherapy, radiotherapy, and immunotherapy, PM prognosis remains poor, necessitating more effective, multimodal strategies. Hyperthermic intrathoracic chemoperfusion (HITHOC) has emerged as a promising adjunct to cytoreductive surgery by delivering heated chemotherapy directly to the pleural cavity, potentially improving survival—especially in patients with epithelioid PM. Combining HITHOC with post-surgical immunotherapy represents a novel approach to enhancing both local and systemic anti-tumor responses and targeting microscopic disease and distant metastases. This review explores surgical outcomes after surgery for PM, the therapeutic synergy of HITHOC and immunotherapy, ongoing clinical trials evaluating this multimodal strategy, and its implications for future patient care.
- Open Access
- 5 May 2025
- Published by Elsevier in JTCVS Open
- Vol. 26, 243-254
An alternative approach to repair of giant paraesophageal hernia in selected patients with minimal history of reflux: Analysis of outcomes in more than 100 patients
- 5 May 2025
- Published by Elsevier in JTCVS Open
- Vol. 26, 243-254
Open AccessAn alternative approach to repair of giant paraesophageal hernia in selected patients with minimal history of reflux: Analysis of outcomes in more than 100 patients
- 11 December 2024
- Published by Elsevier in Seminars in Thoracic and Cardiovascular Surgery
- Vol. 37 (1) , 67-74
Treatment of High-Risk Patients with Stage I Non-Small Cell Lung Cancer
- 11 December 2024
- Published by Elsevier in Seminars in Thoracic and Cardiovascular Surgery
- Vol. 37 (1) , 67-74
Treatment of High-Risk Patients with Stage I Non-Small Cell Lung Cancer
- 9 December 2024
- Published by Elsevier in Seminars in Thoracic and Cardiovascular Surgery
- Vol. 37 (1) , 82-88
Systematic Review of Image-Guided Thermal Ablation for Treatment of High-Risk Patients with Stage I Non-Small Cell Lung Cancer
- 9 December 2024
- Published by Elsevier in Seminars in Thoracic and Cardiovascular Surgery
- Vol. 37 (1) , 82-88
Systematic Review of Image-Guided Thermal Ablation for Treatment of High-Risk Patients with Stage I Non-Small Cell Lung Cancer
- Open Access
- 1 November 2022
- Published by AME Publishing Company in Current Challenges in Thoracic Surgery
- Vol. 4, 40
Ablation for treating small pulmonary nodules: radiologic and surgical approach and perspectives
Review Article Ablation for treating small pulmonary nodules: radiologic and surgical approach and perspectives Damian E. Dupuy, Janine Zuromski, Arjun Pennathur
- 1 November 2022
- Published by AME Publishing Company in Current Challenges in Thoracic Surgery
- Vol. 4, 40
Open AccessAblation for treating small pulmonary nodules: radiologic and surgical approach and perspectives
Review Article Ablation for treating small pulmonary nodules: radiologic and surgical approach and perspectives Damian E. Dupuy, Janine Zuromski, Arjun Pennathur